![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, March 19, 2010 7:36:34 AM
DOW JONES NEWSWIRES
AP Pharma Inc. (APPA:$2.06,00$0.50,0032.05%) said U.S. regulators need more answers about the company's lead drug candidate, a treatment for chemotheraphy-induced nausea, before they can approve the company's new-drug application.
The Food and Drug Administration said it has some worries about the dosing system, manufacturing of and data about APF530, which would be the second drug on the market for chemotherapy-induced nausea and vomiting if approved. Shares plunged 63% to 76 cents on the news. The stock had doubled the past three months.
AP Pharma (APPA:$2.06,00$0.50,0032.05%) has been waiting on FDA approval before pursuing partnership talks for marketing the drug in earnest. Although the company could market the drug on its own, Chief Executive Ronald Prentki had indicated the company was willing to wait for approval in order to get the best deal.
Friday, the company said the FDA was worried about the drug's two-syringe dosing system, including potential problems transferring material from one syringe to the other or the possible risk of improper administration.
The agency also identified deficiencies at some of AP Pharma's (APPA:$2.06,00$0.50,0032.05%) contract manufacturing facilities, which must be resolved. It wants the company to switch to a terminal sterilization process before approving the drug.
Although it didn't request any more clinical studies, the FDA wanted AP Pharma (APPA:$2.06,00$0.50,0032.05%) to review its existing late-stage trial data and reanalyze it. It requested the company do studies related to bioavailability, metabolism and heart arrhythmia, which AP Pharma (APPA:$2.06,00$0.50,0032.05%) said it expect won't take long. The agency also declined the company's request to waive a thorough QT study, which AP Pharma (APPA:$2.06,00$0.50,0032.05%) also said shouldn't take long.
The company had to cut more than a third of its work force last year and shelve several early-stage development programs to conserve cash, vesting a lot of its future success in APF530. The treatment would compete with Eisai Co.'s (ESALF:$39.3254,$0.0000,0.00%) ( 4523.TO, ESALY) Aloxi.
-By Joan E. Solsman, Dow Jones Newswires; 212-416-2291; joan.solsman@ dowjones.com
Click here to go to Dow Jones NewsPlus, a web front page of today's most important business and market news, analysis and commentary: http:// www.djnewsplus.com/nae/al?rnd=T8y1viD%2BeszTXJbWSDhHaQ%3D%3D. You can use this link on the day this article is published and the following day.
(END) Dow Jones Newswires
03-19-100735ET
Copyright (c) 2010 Dow Jones & Company, Inc.
Recent HRTX News
- Heron Therapeutics Announces Appointment of Brett Fleshman as Chief Business Officer • PR Newswire (US) • 09/03/2024 12:00:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/06/2024 08:35:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:05:13 PM
- Heron Therapeutics Announces Second Quarter 2024 Financial Results and Narrows Financial Guidance • PR Newswire (US) • 08/06/2024 08:05:00 PM
- Heron Therapeutics to Report Second Quarter 2024 Financial Results On Tuesday, August 6, 2024 • PR Newswire (US) • 07/30/2024 08:05:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 01:54:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 01:44:15 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/22/2024 01:32:57 PM
- Heron Therapeutics Announces the Inclusion of ZYNRELEF® as a Qualifying Product Under the Proposed 2025 Non-Opioid Policy for Pain Relief Under the OPPS and the ASC Payment System • PR Newswire (US) • 07/15/2024 12:00:00 PM
- Heron Therapeutics Announces Acceptance of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") • PR Newswire (US) • 07/02/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/18/2024 08:43:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/17/2024 06:21:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/07/2024 01:34:07 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 05/31/2024 03:08:56 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 12:05:11 PM
- Heron Therapeutics Announces Prior Approval Supplement Submission to the FDA for ZYNRELEF® Vial Access Needle ("VAN") • PR Newswire (US) • 05/29/2024 12:05:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 12:05:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 12:05:13 PM
- Heron Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Corporate Updates • PR Newswire (US) • 05/07/2024 12:00:00 PM
- Heron Therapeutics to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024 • PR Newswire (US) • 04/24/2024 12:00:00 PM
- Heron Therapeutics to Host Investor Day on May 15, 2024 in New York City • PR Newswire (US) • 04/11/2024 08:05:00 PM
- Heron Therapeutics Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference • PR Newswire (US) • 03/28/2024 08:05:00 PM
- Biotech Finds Mid-Week Success Following Q4 Earnings Release • AllPennyStocks.com • 03/13/2024 08:25:00 PM
- Heron Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Corporate Updates • PR Newswire (US) • 03/12/2024 08:05:00 PM
- Global Markets Await U.S. Inflation Report: Mixed Movements in Pre-Market Trading • IH Market News • 03/12/2024 11:22:57 AM
Maybacks Global and Inventel Products To Launch Global 24 Hour Shopping Channel • AHRO • Sep 3, 2024 9:15 AM
UC Asset announces plan of management stock buyback • UCASU • Sep 3, 2024 9:00 AM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM